The nucleotide sequence of the genomic segment encoding the major antigen, VP6, of human rotavirus strain RV3 was determined for the virus isolated from faeces. This was compared with the sequence of the cognate gene of tissue culture-adapted candidate vaccine virus that was derived from RV3 and had been passaged 30 times. A single silent nucleotide difference was detected between the two genes and the deduced amino acid sequence for both showed the highest degree of identity (~> 97"5 %) with the VP6 proteins of rotavirus strains belonging to the same subgroup. The amino acid residues that might affect VP6 subgroup epitope type from RV3 and other viruses of the same or different subgroups were compared. The commonality of particular amino acids among strains of different subgroups suggests that the presence of all subgroup-specific amino acids may be necessary for subgroup determination.
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The human rotavirus strain RV3 (serotype G3P6, subgroup II), was isolated from a neonate with asymptomatic infection in Melbourne, Australia, in 1977 (Albert & Bishop, 1984) . This virus is believed to be naturally attenuated and is representative of a strain endemic in an obstetric hospital nursery that protected against clinically severe disease on reinfection (Bishop et al., 1983) . RV3 has, therefore, been developed as a candidate rotavirus vaccine. However, the basis of attenuation is unknown and little molecular or genetic information is available about this strain. To date, only one of its 11 genomic dsRNA segments, that encoding the major outer capsid protein VP7, has been sequenced (Huang et al., 1989) . Additional data is required so that studies can be conducted in order to determine virus stability after replication in the intestinal tract during vaccine trials.
In this study, we have determined the nucleotide sequence of the gene encoding the major inner capsid protein and major viral antigen, VP6, of RV3. VP6 carries the group and subgroup determinants of rotaviruses and five groups (A to E) are currently defined (Pedley et al., 1986) . The presence or absence of particular epitopes on VP6, as determined by reactivity with subgroup-specific monoclonal antibodies (MAbs), allows Group A rotaviruses, the major cause of acute gastroenteritis in children worldwide, to be further
The nucleotide sequence data reported in this paper have been deposited in the GenBank nucleotide sequence database and have been assigned the accession number U04741.
classified as subgroup I, II, I & II or non-I/II (Estes & Cohen, 1989) .
The viruses used in this study were obtained from the original faecal material from which RV3 was isolated and also from candidate vaccine virus adapted to growth in African Green monkey kidney cells and then passaged in culture 30 times, including triple-plaque purification between passages 19 and 23. Genomic dsRNA was purified from the faeces and from the passage 30 vaccine virus as described previously (Palombo et at., 1993) . Complementary DNA of gene segment 6 (encoding VP6) was synthesized and amplified by the reverse transcriptase (RT)/PCR method of Gentsch et al. (1992) . The primers that were used were complementary to the 3' ends of each RNA strand of segment 6 as determined from published sequences of other Group A rotaviruses. The cDNA was gel-purified and cloned into plasmid pGEM-3zf (Promega). Three individual recombinants from independent PCR reactions for both faecal-and vaccine-derived virus were isolated and both strands of the cloned DNA were sequenced by thermal cycling dideoxynucleotide sequencing using the fmol DNA Sequencing System (Promega) and a series of oligonucleotide primers.
The RV3 gene 6 contained one long open reading frame encoding a polypeptide of 397 amino acids in length (Fig. 1) . This is in agreement with the size of VP6 as determined for the majority of other Group A rotaviruses (Both et at., 1984; Gorziglia et at., 1988) . The cloned RV3 gene 6 also contained non-coding regions of 23 (5' end) and 142 nucleotides (3' end), although the lengths and precise sequences of these may have been 0001-2534 © 1994 SGM 
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masked by the primers used in amplification (Fig. 1) .
Comparison of the faecal-and passage 30 vaccinederived virus showed a single nucleotide base substitution at nucleotide 263. This substitution results in an ACT to ACC change at codon position 80, although there is no resultant amino acid substitution (Fig. 1) .
Comparison of the RV3 VP6 deduced amino acid sequence with other published sequences showed that RV3 was closely related to the other subgroup II (SGII) rotavirus strains Wa and Gottfried (Both et al., 1984; Gorziglia et al., 1988) (Both et al., 1984) , Gottfried (Gott; Gorziglia et al., 1988) , SAll (Both et al., 1984) , YM (Lopez & Arias, 1993) , RF (Gorziglia et al., 1988 ), 1076 (Gorziglia et al., 1988 , FI-14 (Gorziglia et al., 1988) and H-2 (Gorziglia et al., 1988) have been published.
non-I/II strains ranged between 89"7% and 91.9%. A recent comparison of Group A rotavirus VP6 sequences identified five potential amino acids (amino acids 56, 120, 315, 339 and 348) that may contribute to subgroup specificity (Lopez & Arias, 1993) . RV3 shares the amino acids that have been suggested to contribute to SGII specificity with Wa and Gottfried (at positions 315, 339 and 348; Fig. 2 ). Amino acids 56 and 120 have been suggested to be involved in subgroup I (SGI) specificity since they are conserved in SGI and SGI/II strains whereas SGII strains have a different amino acid at each residue (Lopez & Arias, 1993) . However, RV3 possesses an isoleucine at residue 56 which is conserved in SA11 (Fig. 2) and other SGI strains. In contrast, other SGII strains have valine conserved at this site (Fig. 2) .
This sequence data suggested that RV3 may exhibit subgroup antigenicity in a different manner from other SGII strains. To test this, the SGI-specific, 255/60, and SGII-specific, 631/9, MAbs (provided by H. Greenberg) were titrated against RV3 and strain Wa in an enzyme immunoassay. Both viruses reacted to the same endpoint titres of antibodies (data not shown). These results suggest that (i) residue 56 may not be involved in subgroup specificity or (ii) the SGI-specific MAb does not bind at position 56. If the latter interpretation is correct, this would indicate that residues 56 and 120 are part of different epitopes. Evidence that this is the case is supported by the finding that group-specific MAbs are immunoreactive with fragments of bovine rotavirus RF VP6 and with synthetic heptapeptides derived from VP6. (Kohli et al., 1992; Kohli et al., 1993) . However, the binding of subgroup-specific MAbs to the trimeric form of VP6, but not to VP6 monomers in Western blot analysis suggests that the subgroup epitopes may be conformational in nature (Gorziglia et al., 1988) .
To further examine the role of the five potential subgroup-determining amino acids, partial segment 6 sequences were derived for the SGII strains RV4, M37 and P, and the amino acids present at residues 56, 120, 315, 339 and 348 were determined (Table 1) . The subgroup specificities of strains RV4, M37 and P were determined using the MAbs 255/60 and 631/9. All were confirmed as SGII strains and all contained identical amino acids at the proposed SGII-determining residues (amino acids 315,339 and 348). Strains M37, P and RV3, possessed an isoleucine at amino acid 56, which is conserved among SGI strains, but an alanine, associated with SGII strains, at amino acid 120. In contrast, strain RV4 contained a serine at amino acid 120, associated with SGI strains, but a valine at amino acid 56, previously conserved among SGII strains. These data suggest that SGI specificity is dependent upon the presence of both isoleucine and serine at amino acid positions 56 and 120 respectively, providing further evidence that the SGI epitopes may be conformational. However, the fact that strain H-2 contains both these amino acids at residues 56 and 120 yet is not recognized by SGI MAbs (Table 1) indicates that residues in addition to those at positions 56 and 120 are required for subgroup classification.
The data presented in this report provide further molecular information on the candidate human rotavirus vaccine strain, RV3. In addition, it extends the limited number of VP6 genes from subgroup II strains that have been sequenced. We have shown that the presence of all the subgroup-specific amino acid residues examined may be required for subgroup determination. In turn, those residues proposed to contribute to SGI epitopes (at residues 56 and 120) may not be the only ones involved in subgroup determination. It is possible, therefore, that subgroup determination may not be predicted solely by primary amino acid sequence comparisons.
We have shown that the genomic segment 6 of RV3 exhibits genetic stability after tissue culture adaptation and multiple passages of the virus. In contrast, five deduced amino acid differences have been detected in the VP4 protein of strain Wa after adaptation and multiple passages in ttepG2 cells (Kitamoto et al., 1993) . This is not unexpected given the association of VP4 with host range restriction and enhanced penetration of the virus (Estes & Cohen, 1989) . For further information on the genetic stability of RV3, particularly in relation to the genes encoding the outer capsid proteins VP4 and VP7, it is necessary to monitor changes in the genetic structure of RV3 during vaccine trials and, therefore, to detect any potential reversion of this strain in vivo. Use of mutagenesis studies may serve to characterize further amino acid residues that may contribute to subgroup determination.
